Drug Profile
Affitope PD01
Alternative Names: ACI-7104; ACI-7104.056; Affitope-PD01A; anti-a-syn vaccine; Parkinson's disease vaccine - AFFiRiS; PD 01; PD-01ALatest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator AFFiRiS
- Developer AC Immune; AFFiRiS
- Class Antiparkinsonians; Peptide vaccines
- Mechanism of Action Alpha-synuclein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Parkinson's disease
- No development reported Multiple system atrophy
Most Recent Events
- 04 Aug 2023 AC Immune plans phase II VACSYN trial for Parkinson’s disease (SC), in the H2 of 2023
- 24 Jul 2023 Phase-II clinical trials in Parkinson's disease (Early-stage disease, Treatment-experienced) in United Kingdom (IM) (NCT06015841)
- 24 Jul 2023 Phase-II clinical trials in Parkinson's disease (Early-stage disease, Treatment-experienced) in Spain (IM) (NCT06015841)